Free tool
FAERS Monitor: Sirturo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204384 or its brand name (Sirturo, Bedaquiline Fumarate). Reports on generic versions are filed under their own applications.
Reports
1,441
Serious
1,379
96% of reports
Hospitalization
479
Death reported
341
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- electrocardiogram qt prolonged223
- off label use174
- hepatotoxicity149
- anaemia146
- neuropathy peripheral109
- nausea93
- death73
- intentional product use issue72
- vomiting72
- decreased appetite46
- dyspnoea46
- dizziness44
- hypokalaemia40
- asthenia34
- headache34
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 21 |
| 2016 | 32 |
| 2017 | 74 |
| 2018 | 199 |
| 2019 | 266 |
| 2020 | 155 |
| 2021 | 77 |
| 2022 | 193 |
| 2023 | 145 |
| 2024 | 119 |
| 2025 | 102 |
| 2026 | 57 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,718 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatotoxicitySignal | 149 | 98.3 | 84.4 | 14,177 |
| electrocardiogram qt prolongedSignal | 223 | 91.1 | 80.7 | 19,684 |
| neuropathy peripheralSignal | 109 | 16.7 | 14.0 | 1,603 |
| hypokalaemiaSignal | 40 | 12.7 | 9.3 | 419 |
| intentional product use issueSignal | 72 | 12.0 | 9.6 | 718 |
| anaemiaSignal | 146 | 11.2 | 9.6 | 1,355 |
| off label useSignal | 174 | 2.9 | 2.5 | 224 |
| decreased appetiteSignal | 46 | 2.9 | 2.2 | 56 |
| vomitingSignal | 72 | 2.2 | 1.8 | 49 |
| nausea | 93 | 1.7 | 1.4 | 28 |
| asthenia | 34 | 1.3 | 0.9 | 2 |
| dizziness | 44 | 1.3 | 1.0 | 3 |
| death | 73 | 1.2 | 1.0 | 3 |
| dyspnoea | 46 | 1.2 | 0.9 | 1 |
| headache | 34 | 0.8 | 0.6 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.